Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, which reduces neurotransmitter release involved in pain signalling and neuronal excitability. That’s the mechanism. It’s why Pregabalin works in neuropathic pain when standard analgesics fail — those don’t touch the same pathway — and why it also has a place in anxiety and epilepsy, where neuronal over-excitability is the core problem.
Strava Healthcare manufactures Pregabalin capsules in India as a Schedule H1 product for licensed pharmaceutical distributors, hospital chains, and regulated export markets.
Pregabalin is exported to countries like Ghana, Nigeria, Sudan, South Sudan, Somalia, Kenya, Uganda, Kenya, Cambodia, Cameroon, Chile, Colombia, DRC Congo, Djibouti, and Dominic republic, Iran, Kazakhstan, Lesotho, Malawi, Myanmar and Niger.
Indications
Diabetic peripheral neuropathy, post herpetic neuralgia, fibromyalgia, central neuropathic pain from spinal cord injury, generalised anxiety disorder (approved in several markets), partial-onset seizures as adjunctive therapy, and chemotherapy-induced peripheral neuropathy (off-label but clinically used).
Dosing: what prescribers need to know?
Starting dose is typically 75 mg twice daily or 150 mg/day, titrated over 1–2 weeks based on response and tolerability. The effective range for neuropathic pain sits at 150–600 mg/day in two or three divided doses. Renal function is the key variable affecting clearance — dose adjustment is needed when creatinine clearance drops below 60 mL/min. don’t stop abruptly; taper over at least a week.
Manufacturing
GMP-certified, Schedule M and Schedule H1 compliant. Batch testing covers assay, content uniformity, dissolution, related substances, and microbiological purity. Third-party COAs on request.
For B2B & Pharma Partners
Contract manufacturing with custom strengths and Schedule H1-compliant labelling. Private label capsules for licensed distributors. Export supply with dossier support and COPP available.
Product Specifications
| Parameter | Details |
|---|---|
| Active Ingredient | Pregabalin |
| Strengths | 75 mg / 150 mg / 300 mg |
| Dosage form | Hard gelatin capsule |
| Pack Sizes | 10s blister; 100s bottle |
| Storage | Below 30°C, protected from moisture |
| Shelf Life | 24 months |
Frequently Asked Questions
Some pain reduction usually shows within 1–2 weeks. Maximum effect takes 4–8 weeks. If there’s no meaningful response at a tolerated therapeutic dose after 8 weeks, further dose escalation is unlikely to help. Worth communicating this clearly at the prescribing end early discontinuation because patients expect faster results is common and avoidable.
Dizziness and drowsiness are the most common, both dose-dependent. They tend to be worst in the first couple of weeks and often settle with continued use. Peripheral oedema, weight gain, and blurred vision occur less often. The CNS effects are the main reason to titrate slowly in older patients.
Schedule H1 status in India reflects a recognised misuse and dependence risk, particularly at higher doses. Prescribers should factor this in for patients with a history of substance misuse. That said, the benefit-risk balance for neuropathic pain and anxiety is well-established this isn’t a reason to avoid the drug in appropriate clinical settings, just a reason for monitoring and considered prescribing.